Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations

• Main Authors: Sabina Mugusi (Author), Abiy Habtewold (Author), Eliford Ngaimisi (Author), Wondwossen Amogne (Author), Getnet Yimer (Author), Omary Minzi (Author), Eyasu Makonnen (Author), Christopher Sudfeld (Author), Jürgen Burhenne (Author), Eleni Aklillu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2020-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Efavirenz-based combination antiretroviral-therapy (cART) is the recommended regimen during tuberculosis (TB) therapy. In a multi-national parallel prospective-cohort study, we investigated the impact of population and pharmacogenetic variations for efavirenz pharmacokinetics, auto-induction, and im...